Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the disease before symptoms arise. Freenome, one of the companies racing to commercialize the first such screening test, on Wednesday announced it raised $270 million—money it plans to accelerate a clinical study of an experimental screening product designed to detect signs of colorectal cancer. The company also plans to explore which cancers it will target next.

Investors have pumped millions this year into companies competing to commercialize a liquid biopsy cancer diagnostic, a test that can find early signs of cancer from... Read more »

Reprints | Share: